Actively Recruiting
Assessing the Safety and Accuracy of the RIGHTEST iFree 2 Continuous Glucose Monitoring System in Pregnant Women with Diabetes Mellitus
Led by Bionime Corporation · Updated on 2026-11-02
104
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the accuracy and safety of the RIGHTEST iFree 2 Continuous Glucose Monitoring CGM System in pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes. This study involves about 104 women at sites in Germany and Taiwan. It aims to compare sensor glucose readings with laboratory blood glucose measurements to assess how well the system works over its intended 15-day use period. Participants will wear two CGM sensors, one on each upper arm, for up to 15 days. During this time, they will undergo one clinic visit lasting up to six hours, where blood samples will be taken every 15 minutes to compare with sensor data. The study will also evaluate sensor performance across glucose ranges, sensor data consistency, alert accuracy, and sensor survival. Safety assessments include monitoring for adverse events and skin reactions at sensor sites, with a follow-up after sensor removal. Throughout the study, participants will be monitored for side effects and device accuracy. Researchers will collect data on glucose levels during the sampling sessions on specific days within the wear period. Safety follow-up will occur within seven days after sensor removal. Participation lasts for the 15-day sensor wear period plus the follow-up, with detailed assessments during the clinic visit and ongoing monitoring of sensor performance and safety.
CONDITIONS
Brief Title
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study
Research Team
M
Mary Ho
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here